Finoriq research workspace
ACTUATE THERAPEUTICS, INC. (ACTU) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for ACTUATE THERAPEUTICS, INC. (ACTU).
Company Snapshot
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
- Company
- ACTUATE THERAPEUTICS, INC. (ACTU)
- Ticker
- ACTU
- Market Cap
- $33.4M
- Latest Price
- $1.395
- Industry
- Biotech & Pharma
ACTUATE THERAPEUTICS, INC. (ACTU) Recent Insider Transactions
Recent market insider transaction records indexed for ACTUATE THERAPEUTICS, INC. (ACTU).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| THOMSON TODD SCommon Stock | S | Disposed | -$1.6M | 2026-01-05 |
| Kairos Venture Partners II, L.P.Common Stock | S | Disposed | -$1.6M | 2026-01-05 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.